Skip to main content
2026 AAOMS 108th Annual Meeting Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Ticketed <br><i>This session/event requires a ticket.</i>
Ticketed
This session/event requires a ticket.
In-person only<br><i>This session is offered in-person only.</i>
In-person only
This session is offered in-person only.
On-demand<br><i>On-demand session available beginning Sept. 28.</i>
On-demand
On-demand session available beginning Sept. 28.
Recorded<br><i>This session will be recorded and available beginning Oct. 19</i>
Recorded
This session will be recorded and available beginning Oct. 19
Sold Out<br><i>This ticketed session/event is sold out.</i>
Sold Out
This ticketed session/event is sold out.

R. B. Bell, DDS, MD, FACS

Executive Medical Director
Providence Cancer Institute of Oregon
Portland, Oregon

R. Bryan Bell, MD, DDS, FACS, FRCS(Ed) is a oral and maxillofacial/head and neck surgeon, researcher and executive leader focused on immunotherapy strategies to improve outcomes for patients with cancer. As Executive Medical Director of the Providence Cancer Institute of Oregon he leads the oncology service line for one of the largest healthcare systems in the Pacific Northwest; as Director of the Earle A. Chiles Research, Providence’s translational research arm, he leads research efforts that for more than 30 years have focused on immunotherapy- from discovery to first in human clinical trials. Since 2010, he and his collaborators at Providence have made important discoveries into the prognostic significance and therapeutic potential of CD8 T cell subsets; dissected the role for dendritic cell subpopulations in activating new and existing T cell responses in tumor draining lymph nodes following radiation therapy and surgery; and showed that intact draining lymphatics are critical for an effective response to immunotherapy. His group conducted a series of neoadjuvant immunotherapy trials in which tumor and matching blood samples were interrogated to better understand immune response; completed enrollment of the first study to combine a multivalent vaccine (DPV-001) containing cancer’s dark matter; initiated a first in human trial of adoptively transferred CD8 “DP TIL”; led a series of potentially paradigm-changing, lymphatic-sparing neoadjuvant immunoradiotherapy trials; and participated in numerous industry-sponsored trials, including Keynote 689, which showed improved survival & established neoadjuvant and adjuvant pembrolizumab as a new standard of care for patients with locally advanced head and neck cancer. In addition, he has worked to develop technologically advanced methods to enhance the effectiveness of head and neck cancer surgery, including virtual surgical planning, transoral robotic surgery and sentinel lymph node biopsy. His work has been published in more than 350 scientific articles and book chapters and he is co-author of two major textbooks, including "Oral, Head and Neck Oncology and Reconstructive Surgery". Amongst his honors, he has been awarded Fellowship in the Royal College of Surgeons of Edinburgh, Ad Hominem.

Presentation(s):